Metzger Michael A 4
4 · Syndax Pharmaceuticals Inc · Filed Sep 8, 2025
Insider Transaction Report
Form 4
Metzger Michael A
DirectorChief Executive Officer
Transactions
- Sale
Common Stock
2025-09-08$16.41/sh−157,307$2,582,021→ 298,661 total - Exercise/Conversion
Common Stock
2025-09-08$10.90/sh+157,307$1,714,646→ 455,968 total - Exercise/Conversion
Stock options (Right to buy)
2025-09-08+157,307→ 0 totalExercise: $10.90Exp: 2025-09-09→ Common Stock (157,307 underlying)
Footnotes (3)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person solely covering equity grants with expiration dates prior to September 10, 2025. Following the sales reported in this Form 4, the Reporting Person has a total of 1,319,634 options to purchase shares of common stock that are vested and immediately exercisable and a total of 651,241 options to purchase shares of common stock that have not yet vested.
- [F2]The sale prices ranged from $16.21 to $17.06.
- [F3]This option is fully vested.